nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—Valrubicin—urinary bladder cancer	0.17	0.757	CrCtD
Epirubicin—Anthracyclines—Doxorubicin—urinary bladder cancer	0.098	0.427	CiPCiCtD
Epirubicin—UGT2B7—urinary bladder cancer	0.0963	1	CbGaD
Epirubicin—Topoisomerase Inhibitors—Etoposide—urinary bladder cancer	0.0804	0.35	CiPCiCtD
Epirubicin—prostate cancer—urinary bladder cancer	0.0719	0.552	CtDrD
Epirubicin—testicular cancer—urinary bladder cancer	0.0585	0.449	CtDrD
Epirubicin—Doxorubicin—urinary bladder cancer	0.0546	0.244	CrCtD
Epirubicin—Topoisomerase Inhibitors—Doxorubicin—urinary bladder cancer	0.0512	0.223	CiPCiCtD
Epirubicin—TOP2A—Valrubicin—urinary bladder cancer	0.0447	0.394	CbGbCtD
Epirubicin—Idarubicin—Valrubicin—urinary bladder cancer	0.0365	0.252	CrCrCtD
Epirubicin—Doxorubicin—Valrubicin—urinary bladder cancer	0.0365	0.252	CrCrCtD
Epirubicin—Daunorubicin—Valrubicin—urinary bladder cancer	0.0365	0.252	CrCrCtD
Epirubicin—DHCR7—Doxorubicin—urinary bladder cancer	0.0177	0.156	CbGbCtD
Epirubicin—AURKA—Doxorubicin—urinary bladder cancer	0.0177	0.156	CbGbCtD
Epirubicin—YWHAG—Doxorubicin—urinary bladder cancer	0.0177	0.156	CbGbCtD
Epirubicin—Daunorubicin—Doxorubicin—urinary bladder cancer	0.0117	0.0812	CrCrCtD
Epirubicin—Idarubicin—Doxorubicin—urinary bladder cancer	0.0117	0.0812	CrCrCtD
Epirubicin—Valrubicin—Doxorubicin—urinary bladder cancer	0.0117	0.0812	CrCrCtD
Epirubicin—TOP2A—Etoposide—urinary bladder cancer	0.00527	0.0465	CbGbCtD
Epirubicin—TOP2A—Doxorubicin—urinary bladder cancer	0.00359	0.0317	CbGbCtD
Epirubicin—ABCC1—Etoposide—urinary bladder cancer	0.00292	0.0258	CbGbCtD
Epirubicin—ABCC1—Doxorubicin—urinary bladder cancer	0.00199	0.0176	CbGbCtD
Epirubicin—ABCC1—Methotrexate—urinary bladder cancer	0.00193	0.017	CbGbCtD
Epirubicin—CHD1—prostate gland—urinary bladder cancer	0.000634	0.0598	CbGeAlD
Epirubicin—CHD1—seminal vesicle—urinary bladder cancer	0.000536	0.0505	CbGeAlD
Epirubicin—DHCR7—prostate gland—urinary bladder cancer	0.000427	0.0403	CbGeAlD
Epirubicin—CHD1—urethra—urinary bladder cancer	0.000424	0.04	CbGeAlD
Epirubicin—YWHAG—prostate gland—urinary bladder cancer	0.000392	0.037	CbGeAlD
Epirubicin—DHCR7—seminal vesicle—urinary bladder cancer	0.000361	0.0341	CbGeAlD
Epirubicin—UGT2B7—prostate gland—urinary bladder cancer	0.000354	0.0334	CbGeAlD
Epirubicin—AURKA—renal system—urinary bladder cancer	0.000348	0.0328	CbGeAlD
Epirubicin—CHD1—female reproductive system—urinary bladder cancer	0.000346	0.0326	CbGeAlD
Epirubicin—YWHAG—seminal vesicle—urinary bladder cancer	0.000332	0.0313	CbGeAlD
Epirubicin—Daunorubicin—POR—urinary bladder cancer	0.000321	0.439	CrCbGaD
Epirubicin—CHD1—vagina—urinary bladder cancer	0.000313	0.0295	CbGeAlD
Epirubicin—PLA2G4A—prostate gland—urinary bladder cancer	0.000293	0.0276	CbGeAlD
Epirubicin—DHCR7—urethra—urinary bladder cancer	0.000286	0.027	CbGeAlD
Epirubicin—AURKA—female reproductive system—urinary bladder cancer	0.000279	0.0263	CbGeAlD
Epirubicin—TOP2A—prostate gland—urinary bladder cancer	0.000278	0.0262	CbGeAlD
Epirubicin—YWHAG—smooth muscle tissue—urinary bladder cancer	0.000278	0.0262	CbGeAlD
Epirubicin—YWHAG—renal system—urinary bladder cancer	0.000267	0.0252	CbGeAlD
Epirubicin—YWHAG—urethra—urinary bladder cancer	0.000263	0.0248	CbGeAlD
Epirubicin—Doxorubicin—POR—urinary bladder cancer	0.000261	0.356	CrCbGaD
Epirubicin—AURKA—vagina—urinary bladder cancer	0.000252	0.0238	CbGeAlD
Epirubicin—PLA2G4A—seminal vesicle—urinary bladder cancer	0.000247	0.0233	CbGeAlD
Epirubicin—UGT2B7—renal system—urinary bladder cancer	0.000241	0.0228	CbGeAlD
Epirubicin—DHCR7—female reproductive system—urinary bladder cancer	0.000233	0.022	CbGeAlD
Epirubicin—YWHAG—female reproductive system—urinary bladder cancer	0.000214	0.0202	CbGeAlD
Epirubicin—DHCR7—vagina—urinary bladder cancer	0.000211	0.0199	CbGeAlD
Epirubicin—PLA2G4A—smooth muscle tissue—urinary bladder cancer	0.000207	0.0195	CbGeAlD
Epirubicin—CHD1—lymph node—urinary bladder cancer	0.000202	0.0191	CbGeAlD
Epirubicin—PLA2G4A—renal system—urinary bladder cancer	0.000199	0.0188	CbGeAlD
Epirubicin—PLA2G4A—urethra—urinary bladder cancer	0.000196	0.0185	CbGeAlD
Epirubicin—YWHAG—vagina—urinary bladder cancer	0.000194	0.0183	CbGeAlD
Epirubicin—UGT2B7—female reproductive system—urinary bladder cancer	0.000193	0.0182	CbGeAlD
Epirubicin—ABCC1—prostate gland—urinary bladder cancer	0.000167	0.0158	CbGeAlD
Epirubicin—AURKA—lymph node—urinary bladder cancer	0.000163	0.0154	CbGeAlD
Epirubicin—PLA2G4A—female reproductive system—urinary bladder cancer	0.00016	0.0151	CbGeAlD
Epirubicin—Doxorubicin—NQO1—urinary bladder cancer	0.00015	0.205	CrCbGaD
Epirubicin—PLA2G4A—vagina—urinary bladder cancer	0.000144	0.0136	CbGeAlD
Epirubicin—ABCC1—seminal vesicle—urinary bladder cancer	0.000142	0.0133	CbGeAlD
Epirubicin—TOP2A—vagina—urinary bladder cancer	0.000137	0.0129	CbGeAlD
Epirubicin—DHCR7—lymph node—urinary bladder cancer	0.000136	0.0129	CbGeAlD
Epirubicin—CHD1—Idarubicin—Valrubicin—urinary bladder cancer	0.000128	0.161	CbGdCrCtD
Epirubicin—CHD1—Daunorubicin—Valrubicin—urinary bladder cancer	0.000128	0.161	CbGdCrCtD
Epirubicin—CHD1—Doxorubicin—Valrubicin—urinary bladder cancer	0.000128	0.161	CbGdCrCtD
Epirubicin—YWHAG—lymph node—urinary bladder cancer	0.000125	0.0118	CbGeAlD
Epirubicin—ABCC1—urethra—urinary bladder cancer	0.000112	0.0106	CbGeAlD
Epirubicin—PLA2G4A—lymph node—urinary bladder cancer	9.34e-05	0.00881	CbGeAlD
Epirubicin—TOP2A—lymph node—urinary bladder cancer	8.87e-05	0.00837	CbGeAlD
Epirubicin—ABCC1—vagina—urinary bladder cancer	8.26e-05	0.00779	CbGeAlD
Epirubicin—ABCC1—lymph node—urinary bladder cancer	5.34e-05	0.00504	CbGeAlD
Epirubicin—AURKA—Idarubicin—Valrubicin—urinary bladder cancer	4.2e-05	0.0531	CbGdCrCtD
Epirubicin—AURKA—Daunorubicin—Valrubicin—urinary bladder cancer	4.2e-05	0.0531	CbGdCrCtD
Epirubicin—AURKA—Doxorubicin—Valrubicin—urinary bladder cancer	4.2e-05	0.0531	CbGdCrCtD
Epirubicin—CHD1—Idarubicin—Doxorubicin—urinary bladder cancer	4.11e-05	0.0519	CbGdCrCtD
Epirubicin—CHD1—Daunorubicin—Doxorubicin—urinary bladder cancer	4.11e-05	0.0519	CbGdCrCtD
Epirubicin—PLA2G4A—Raltitrexed—Methotrexate—urinary bladder cancer	3.95e-05	0.0498	CbGdCrCtD
Epirubicin—AURKA—Teniposide—Etoposide—urinary bladder cancer	2.8e-05	0.0354	CbGdCrCtD
Epirubicin—TOP2A—Idarubicin—Valrubicin—urinary bladder cancer	1.6e-05	0.0203	CbGdCrCtD
Epirubicin—TOP2A—Doxorubicin—Valrubicin—urinary bladder cancer	1.6e-05	0.0203	CbGdCrCtD
Epirubicin—TOP2A—Daunorubicin—Valrubicin—urinary bladder cancer	1.6e-05	0.0203	CbGdCrCtD
Epirubicin—AURKA—Cytarabine—Gemcitabine—urinary bladder cancer	1.58e-05	0.0199	CbGdCrCtD
Epirubicin—AURKA—Idarubicin—Doxorubicin—urinary bladder cancer	1.35e-05	0.0171	CbGdCrCtD
Epirubicin—AURKA—Daunorubicin—Doxorubicin—urinary bladder cancer	1.35e-05	0.0171	CbGdCrCtD
Epirubicin—TOP2A—Teniposide—Etoposide—urinary bladder cancer	1.07e-05	0.0135	CbGdCrCtD
Epirubicin—TOP2A—Podofilox—Etoposide—urinary bladder cancer	1.07e-05	0.0135	CbGdCrCtD
Epirubicin—YWHAG—Cell Cycle—TERT—urinary bladder cancer	9e-06	0.000669	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—UGT2B7—urinary bladder cancer	8.98e-06	0.000668	CbGpPWpGaD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	8.9e-06	0.000662	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.67e-06	0.000645	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	8.65e-06	0.000643	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—GSTP1—urinary bladder cancer	8.55e-06	0.000635	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	8.41e-06	0.000625	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GSTZ1—urinary bladder cancer	8.28e-06	0.000616	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.27e-06	0.000615	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CYP4B1—urinary bladder cancer	8.25e-06	0.000613	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	8.24e-06	0.000613	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	8.23e-06	0.000612	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—MYC—urinary bladder cancer	8.2e-06	0.00061	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	8.13e-06	0.000605	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—CDKN2A—urinary bladder cancer	8.12e-06	0.000604	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	8.11e-06	0.000603	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—ATM—urinary bladder cancer	8.09e-06	0.000602	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CYP4B1—urinary bladder cancer	8.09e-06	0.000601	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	8.08e-06	0.000601	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	8.06e-06	0.000599	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—CDK4—urinary bladder cancer	8.06e-06	0.000599	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—TYMS—urinary bladder cancer	7.94e-06	0.000591	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	7.92e-06	0.000589	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—NCOR1—urinary bladder cancer	7.85e-06	0.000584	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—GSTM1—urinary bladder cancer	7.85e-06	0.000584	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GSTO2—urinary bladder cancer	7.85e-06	0.000584	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NAT1—urinary bladder cancer	7.85e-06	0.000584	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—RB1—urinary bladder cancer	7.83e-06	0.000583	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—SLC19A1—urinary bladder cancer	7.79e-06	0.000579	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—PTEN—urinary bladder cancer	7.79e-06	0.000579	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	7.74e-06	0.000575	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.72e-06	0.000574	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—IFNA2—urinary bladder cancer	7.71e-06	0.000573	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	7.68e-06	0.000571	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—SLC19A1—urinary bladder cancer	7.64e-06	0.000568	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PRSS3—urinary bladder cancer	7.59e-06	0.000564	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—KRAS—urinary bladder cancer	7.58e-06	0.000563	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	7.52e-06	0.000559	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—GPX1—urinary bladder cancer	7.52e-06	0.000559	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PRSS3—urinary bladder cancer	7.44e-06	0.000554	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—EP300—urinary bladder cancer	7.43e-06	0.000552	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	7.43e-06	0.000552	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—ERCC2—urinary bladder cancer	7.38e-06	0.000549	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—CCNE1—urinary bladder cancer	7.36e-06	0.000547	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SLC19A1—urinary bladder cancer	7.29e-06	0.000542	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	7.28e-06	0.000541	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TYMS—urinary bladder cancer	7.23e-06	0.000537	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—UGT2B7—urinary bladder cancer	7.18e-06	0.000534	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PRSS3—urinary bladder cancer	7.1e-06	0.000528	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—EP300—urinary bladder cancer	7.07e-06	0.000525	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	7.04e-06	0.000524	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	7.03e-06	0.000523	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—RB1—urinary bladder cancer	7e-06	0.000521	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—MTHFR—urinary bladder cancer	6.94e-06	0.000516	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	6.89e-06	0.000512	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—CCND1—urinary bladder cancer	6.86e-06	0.00051	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HDAC4—urinary bladder cancer	6.78e-06	0.000504	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	6.74e-06	0.000501	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	6.7e-06	0.000498	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.67e-06	0.000496	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	6.65e-06	0.000494	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—CDKN1A—urinary bladder cancer	6.64e-06	0.000494	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	6.59e-06	0.00049	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	6.52e-06	0.000485	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP4B1—urinary bladder cancer	6.46e-06	0.000481	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—HRAS—urinary bladder cancer	6.44e-06	0.000479	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—EP300—urinary bladder cancer	6.32e-06	0.00047	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	6.3e-06	0.000469	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TERT—urinary bladder cancer	6.3e-06	0.000468	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	6.28e-06	0.000467	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	6.23e-06	0.000463	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—MYC—urinary bladder cancer	6.16e-06	0.000458	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—CDKN2A—urinary bladder cancer	6.16e-06	0.000458	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—SLC19A1—urinary bladder cancer	6.1e-06	0.000454	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—TYMP—urinary bladder cancer	6.07e-06	0.000451	CbGpPWpGaD
Epirubicin—Dysphagia—Doxorubicin—urinary bladder cancer	6.03e-06	0.000169	CcSEcCtD
Epirubicin—Influenza—Doxorubicin—urinary bladder cancer	6.03e-06	0.000169	CcSEcCtD
Epirubicin—TOP2A—Cytarabine—Gemcitabine—urinary bladder cancer	6.02e-06	0.00761	CbGdCrCtD
Epirubicin—Body temperature increased—Fluorouracil—urinary bladder cancer	6.01e-06	0.000169	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.97e-06	0.000444	CbGpPWpGaD
Epirubicin—Eosinophilia—Doxorubicin—urinary bladder cancer	5.97e-06	0.000168	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—TYMP—urinary bladder cancer	5.95e-06	0.000443	CbGpPWpGaD
Epirubicin—Sweating—Methotrexate—urinary bladder cancer	5.95e-06	0.000167	CcSEcCtD
Epirubicin—ABCC1—Metabolism—PRSS3—urinary bladder cancer	5.95e-06	0.000442	CbGpPWpGaD
Epirubicin—Feeling abnormal—Cisplatin—urinary bladder cancer	5.94e-06	0.000167	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—HDAC4—urinary bladder cancer	5.94e-06	0.000442	CbGpPWpGaD
Epirubicin—Paraesthesia—Etoposide—urinary bladder cancer	5.93e-06	0.000167	CcSEcCtD
Epirubicin—Haematuria—Methotrexate—urinary bladder cancer	5.92e-06	0.000166	CcSEcCtD
Epirubicin—Pancreatitis—Doxorubicin—urinary bladder cancer	5.91e-06	0.000166	CcSEcCtD
Epirubicin—Dyspnoea—Etoposide—urinary bladder cancer	5.89e-06	0.000165	CcSEcCtD
Epirubicin—Somnolence—Etoposide—urinary bladder cancer	5.87e-06	0.000165	CcSEcCtD
Epirubicin—Angina pectoris—Doxorubicin—urinary bladder cancer	5.87e-06	0.000165	CcSEcCtD
Epirubicin—Hepatobiliary disease—Methotrexate—urinary bladder cancer	5.87e-06	0.000165	CcSEcCtD
Epirubicin—Epistaxis—Methotrexate—urinary bladder cancer	5.85e-06	0.000164	CcSEcCtD
Epirubicin—Vomiting—Thiotepa—urinary bladder cancer	5.85e-06	0.000164	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	5.84e-06	0.000434	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	5.82e-06	0.000433	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	5.8e-06	0.000431	CbGpPWpGaD
Epirubicin—Rash—Thiotepa—urinary bladder cancer	5.8e-06	0.000163	CcSEcCtD
Epirubicin—Bronchitis—Doxorubicin—urinary bladder cancer	5.8e-06	0.000163	CcSEcCtD
Epirubicin—Dermatitis—Thiotepa—urinary bladder cancer	5.79e-06	0.000163	CcSEcCtD
Epirubicin—Agranulocytosis—Methotrexate—urinary bladder cancer	5.79e-06	0.000163	CcSEcCtD
Epirubicin—Headache—Thiotepa—urinary bladder cancer	5.76e-06	0.000162	CcSEcCtD
Epirubicin—Decreased appetite—Etoposide—urinary bladder cancer	5.74e-06	0.000161	CcSEcCtD
Epirubicin—Pancytopenia—Doxorubicin—urinary bladder cancer	5.72e-06	0.000161	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.72e-06	0.000425	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	5.71e-06	0.000425	CbGpPWpGaD
Epirubicin—Gastrointestinal disorder—Etoposide—urinary bladder cancer	5.7e-06	0.00016	CcSEcCtD
Epirubicin—Body temperature increased—Cisplatin—urinary bladder cancer	5.7e-06	0.00016	CcSEcCtD
Epirubicin—Fatigue—Etoposide—urinary bladder cancer	5.7e-06	0.00016	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—ATM—urinary bladder cancer	5.66e-06	0.000421	CbGpPWpGaD
Epirubicin—Constipation—Etoposide—urinary bladder cancer	5.65e-06	0.000159	CcSEcCtD
Epirubicin—Pain—Etoposide—urinary bladder cancer	5.65e-06	0.000159	CcSEcCtD
Epirubicin—Neutropenia—Doxorubicin—urinary bladder cancer	5.63e-06	0.000158	CcSEcCtD
Epirubicin—Dysuria—Doxorubicin—urinary bladder cancer	5.63e-06	0.000158	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CDK4—urinary bladder cancer	5.63e-06	0.000419	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	5.63e-06	0.000418	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PPARG—urinary bladder cancer	5.63e-06	0.000418	CbGpPWpGaD
Epirubicin—Hypersensitivity—Fluorouracil—urinary bladder cancer	5.6e-06	0.000157	CcSEcCtD
Epirubicin—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	5.6e-06	0.000157	CcSEcCtD
Epirubicin—Haemoglobin—Methotrexate—urinary bladder cancer	5.6e-06	0.000157	CcSEcCtD
Epirubicin—Hepatitis—Methotrexate—urinary bladder cancer	5.57e-06	0.000156	CcSEcCtD
Epirubicin—Haemorrhage—Methotrexate—urinary bladder cancer	5.57e-06	0.000156	CcSEcCtD
Epirubicin—Pollakiuria—Doxorubicin—urinary bladder cancer	5.57e-06	0.000156	CcSEcCtD
Epirubicin—Asthenia—Gemcitabine—urinary bladder cancer	5.55e-06	0.000156	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	5.54e-06	0.000412	CbGpPWpGaD
Epirubicin—Pharyngitis—Methotrexate—urinary bladder cancer	5.53e-06	0.000155	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—MYC—urinary bladder cancer	5.51e-06	0.000409	CbGpPWpGaD
Epirubicin—Urinary tract disorder—Methotrexate—urinary bladder cancer	5.5e-06	0.000154	CcSEcCtD
Epirubicin—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	5.5e-06	0.000154	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—NAT2—urinary bladder cancer	5.49e-06	0.000408	CbGpPWpGaD
Epirubicin—Weight increased—Doxorubicin—urinary bladder cancer	5.48e-06	0.000154	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—RB1—urinary bladder cancer	5.48e-06	0.000407	CbGpPWpGaD
Epirubicin—Pruritus—Gemcitabine—urinary bladder cancer	5.47e-06	0.000154	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—PLAU—urinary bladder cancer	5.47e-06	0.000407	CbGpPWpGaD
Epirubicin—Nausea—Thiotepa—urinary bladder cancer	5.46e-06	0.000153	CcSEcCtD
Epirubicin—Urethral disorder—Methotrexate—urinary bladder cancer	5.46e-06	0.000153	CcSEcCtD
Epirubicin—Weight decreased—Doxorubicin—urinary bladder cancer	5.45e-06	0.000153	CcSEcCtD
Epirubicin—Feeling abnormal—Etoposide—urinary bladder cancer	5.44e-06	0.000153	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	5.44e-06	0.000405	CbGpPWpGaD
Epirubicin—Hyperglycaemia—Doxorubicin—urinary bladder cancer	5.44e-06	0.000153	CcSEcCtD
Epirubicin—DHCR7—Metabolism—CREBBP—urinary bladder cancer	5.41e-06	0.000402	CbGpPWpGaD
Epirubicin—Pneumonia—Doxorubicin—urinary bladder cancer	5.4e-06	0.000152	CcSEcCtD
Epirubicin—Gastrointestinal pain—Etoposide—urinary bladder cancer	5.4e-06	0.000152	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	5.4e-06	0.000401	CbGpPWpGaD
Epirubicin—ABCC1—Disease—LIG1—urinary bladder cancer	5.38e-06	0.0004	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—NAT2—urinary bladder cancer	5.38e-06	0.0004	CbGpPWpGaD
Epirubicin—Pruritus—Fluorouracil—urinary bladder cancer	5.38e-06	0.000151	CcSEcCtD
Epirubicin—Infestation—Doxorubicin—urinary bladder cancer	5.37e-06	0.000151	CcSEcCtD
Epirubicin—Infestation NOS—Doxorubicin—urinary bladder cancer	5.37e-06	0.000151	CcSEcCtD
Epirubicin—Drowsiness—Doxorubicin—urinary bladder cancer	5.37e-06	0.000151	CcSEcCtD
Epirubicin—Visual impairment—Methotrexate—urinary bladder cancer	5.37e-06	0.000151	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—EP300—urinary bladder cancer	5.36e-06	0.000398	CbGpPWpGaD
Epirubicin—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	5.33e-06	0.00015	CcSEcCtD
Epirubicin—TOP2A—Circadian rythm related genes—TP53—urinary bladder cancer	5.32e-06	0.000395	CbGpPWpGaD
Epirubicin—Hypersensitivity—Cisplatin—urinary bladder cancer	5.31e-06	0.000149	CcSEcCtD
Epirubicin—Diarrhoea—Gemcitabine—urinary bladder cancer	5.29e-06	0.000149	CcSEcCtD
Epirubicin—Renal failure—Doxorubicin—urinary bladder cancer	5.28e-06	0.000148	CcSEcCtD
Epirubicin—Erythema multiforme—Methotrexate—urinary bladder cancer	5.27e-06	0.000148	CcSEcCtD
Epirubicin—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	5.27e-06	0.000148	CcSEcCtD
Epirubicin—Urticaria—Etoposide—urinary bladder cancer	5.25e-06	0.000147	CcSEcCtD
Epirubicin—Stomatitis—Doxorubicin—urinary bladder cancer	5.24e-06	0.000147	CcSEcCtD
Epirubicin—Jaundice—Doxorubicin—urinary bladder cancer	5.24e-06	0.000147	CcSEcCtD
Epirubicin—Body temperature increased—Etoposide—urinary bladder cancer	5.22e-06	0.000147	CcSEcCtD
Epirubicin—Abdominal pain—Etoposide—urinary bladder cancer	5.22e-06	0.000147	CcSEcCtD
Epirubicin—Urinary tract infection—Doxorubicin—urinary bladder cancer	5.22e-06	0.000147	CcSEcCtD
Epirubicin—Conjunctivitis—Doxorubicin—urinary bladder cancer	5.22e-06	0.000147	CcSEcCtD
Epirubicin—Eye disorder—Methotrexate—urinary bladder cancer	5.21e-06	0.000146	CcSEcCtD
Epirubicin—Diarrhoea—Fluorouracil—urinary bladder cancer	5.21e-06	0.000146	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—CCND1—urinary bladder cancer	5.2e-06	0.000387	CbGpPWpGaD
Epirubicin—Tinnitus—Methotrexate—urinary bladder cancer	5.19e-06	0.000146	CcSEcCtD
Epirubicin—Asthenia—Cisplatin—urinary bladder cancer	5.17e-06	0.000145	CcSEcCtD
Epirubicin—Cardiac disorder—Methotrexate—urinary bladder cancer	5.17e-06	0.000145	CcSEcCtD
Epirubicin—TOP2A—Daunorubicin—Doxorubicin—urinary bladder cancer	5.17e-06	0.00653	CbGdCrCtD
Epirubicin—TOP2A—Idarubicin—Doxorubicin—urinary bladder cancer	5.17e-06	0.00653	CbGdCrCtD
Epirubicin—Sweating—Doxorubicin—urinary bladder cancer	5.15e-06	0.000145	CcSEcCtD
Epirubicin—Haematuria—Doxorubicin—urinary bladder cancer	5.12e-06	0.000144	CcSEcCtD
Epirubicin—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	5.08e-06	0.000143	CcSEcCtD
Epirubicin—Epistaxis—Doxorubicin—urinary bladder cancer	5.07e-06	0.000142	CcSEcCtD
Epirubicin—Angiopathy—Methotrexate—urinary bladder cancer	5.05e-06	0.000142	CcSEcCtD
Epirubicin—Sinusitis—Doxorubicin—urinary bladder cancer	5.04e-06	0.000142	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—CDKN1A—urinary bladder cancer	5.03e-06	0.000374	CbGpPWpGaD
Epirubicin—Immune system disorder—Methotrexate—urinary bladder cancer	5.03e-06	0.000141	CcSEcCtD
Epirubicin—Dizziness—Fluorouracil—urinary bladder cancer	5.03e-06	0.000141	CcSEcCtD
Epirubicin—Mediastinal disorder—Methotrexate—urinary bladder cancer	5.02e-06	0.000141	CcSEcCtD
Epirubicin—Agranulocytosis—Doxorubicin—urinary bladder cancer	5.01e-06	0.000141	CcSEcCtD
Epirubicin—Chills—Methotrexate—urinary bladder cancer	5e-06	0.00014	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—GLI1—urinary bladder cancer	4.98e-06	0.00037	CbGpPWpGaD
Epirubicin—Diarrhoea—Cisplatin—urinary bladder cancer	4.93e-06	0.000139	CcSEcCtD
Epirubicin—Alopecia—Methotrexate—urinary bladder cancer	4.92e-06	0.000138	CcSEcCtD
Epirubicin—Vomiting—Gemcitabine—urinary bladder cancer	4.92e-06	0.000138	CcSEcCtD
Epirubicin—Bradycardia—Doxorubicin—urinary bladder cancer	4.91e-06	0.000138	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—RB1—urinary bladder cancer	4.9e-06	0.000364	CbGpPWpGaD
Epirubicin—Mental disorder—Methotrexate—urinary bladder cancer	4.88e-06	0.000137	CcSEcCtD
Epirubicin—Rash—Gemcitabine—urinary bladder cancer	4.88e-06	0.000137	CcSEcCtD
Epirubicin—Dermatitis—Gemcitabine—urinary bladder cancer	4.87e-06	0.000137	CcSEcCtD
Epirubicin—Hypersensitivity—Etoposide—urinary bladder cancer	4.87e-06	0.000137	CcSEcCtD
Epirubicin—Malnutrition—Methotrexate—urinary bladder cancer	4.85e-06	0.000136	CcSEcCtD
Epirubicin—Erythema—Methotrexate—urinary bladder cancer	4.85e-06	0.000136	CcSEcCtD
Epirubicin—Haemoglobin—Doxorubicin—urinary bladder cancer	4.85e-06	0.000136	CcSEcCtD
Epirubicin—Headache—Gemcitabine—urinary bladder cancer	4.85e-06	0.000136	CcSEcCtD
Epirubicin—Vomiting—Fluorouracil—urinary bladder cancer	4.84e-06	0.000136	CcSEcCtD
Epirubicin—Rhinitis—Doxorubicin—urinary bladder cancer	4.84e-06	0.000136	CcSEcCtD
Epirubicin—Haemorrhage—Doxorubicin—urinary bladder cancer	4.82e-06	0.000135	CcSEcCtD
Epirubicin—Hepatitis—Doxorubicin—urinary bladder cancer	4.82e-06	0.000135	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	4.82e-06	0.000358	CbGpPWpGaD
Epirubicin—Hypoaesthesia—Doxorubicin—urinary bladder cancer	4.8e-06	0.000135	CcSEcCtD
Epirubicin—Rash—Fluorouracil—urinary bladder cancer	4.8e-06	0.000135	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	4.8e-06	0.000357	CbGpPWpGaD
Epirubicin—Dermatitis—Fluorouracil—urinary bladder cancer	4.79e-06	0.000135	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—EP300—urinary bladder cancer	4.79e-06	0.000356	CbGpPWpGaD
Epirubicin—Pharyngitis—Doxorubicin—urinary bladder cancer	4.79e-06	0.000134	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.77e-06	0.000355	CbGpPWpGaD
Epirubicin—Headache—Fluorouracil—urinary bladder cancer	4.77e-06	0.000134	CcSEcCtD
Epirubicin—Urinary tract disorder—Doxorubicin—urinary bladder cancer	4.76e-06	0.000134	CcSEcCtD
Epirubicin—ABCC1—Metabolism—TYMP—urinary bladder cancer	4.76e-06	0.000354	CbGpPWpGaD
Epirubicin—Oedema peripheral—Doxorubicin—urinary bladder cancer	4.75e-06	0.000133	CcSEcCtD
Epirubicin—Dysgeusia—Methotrexate—urinary bladder cancer	4.75e-06	0.000133	CcSEcCtD
Epirubicin—Asthenia—Etoposide—urinary bladder cancer	4.74e-06	0.000133	CcSEcCtD
Epirubicin—Connective tissue disorder—Doxorubicin—urinary bladder cancer	4.74e-06	0.000133	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—RRM2—urinary bladder cancer	4.74e-06	0.000352	CbGpPWpGaD
Epirubicin—Urethral disorder—Doxorubicin—urinary bladder cancer	4.73e-06	0.000133	CcSEcCtD
Epirubicin—Back pain—Methotrexate—urinary bladder cancer	4.69e-06	0.000132	CcSEcCtD
Epirubicin—Pruritus—Etoposide—urinary bladder cancer	4.67e-06	0.000131	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—MYC—urinary bladder cancer	4.67e-06	0.000347	CbGpPWpGaD
Epirubicin—Visual impairment—Doxorubicin—urinary bladder cancer	4.65e-06	0.000131	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—RRM2—urinary bladder cancer	4.65e-06	0.000345	CbGpPWpGaD
Epirubicin—Nausea—Gemcitabine—urinary bladder cancer	4.6e-06	0.000129	CcSEcCtD
Epirubicin—Vomiting—Cisplatin—urinary bladder cancer	4.59e-06	0.000129	CcSEcCtD
Epirubicin—Vision blurred—Methotrexate—urinary bladder cancer	4.57e-06	0.000128	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.57e-06	0.00034	CbGpPWpGaD
Epirubicin—Erythema multiforme—Doxorubicin—urinary bladder cancer	4.56e-06	0.000128	CcSEcCtD
Epirubicin—Rash—Cisplatin—urinary bladder cancer	4.55e-06	0.000128	CcSEcCtD
Epirubicin—Dermatitis—Cisplatin—urinary bladder cancer	4.54e-06	0.000128	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—TP53—urinary bladder cancer	4.52e-06	0.000336	CbGpPWpGaD
Epirubicin—Diarrhoea—Etoposide—urinary bladder cancer	4.52e-06	0.000127	CcSEcCtD
Epirubicin—Nausea—Fluorouracil—urinary bladder cancer	4.52e-06	0.000127	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—CREBBP—urinary bladder cancer	4.51e-06	0.000336	CbGpPWpGaD
Epirubicin—Eye disorder—Doxorubicin—urinary bladder cancer	4.51e-06	0.000127	CcSEcCtD
Epirubicin—Ill-defined disorder—Methotrexate—urinary bladder cancer	4.5e-06	0.000126	CcSEcCtD
Epirubicin—Tinnitus—Doxorubicin—urinary bladder cancer	4.5e-06	0.000126	CcSEcCtD
Epirubicin—Anaemia—Methotrexate—urinary bladder cancer	4.48e-06	0.000126	CcSEcCtD
Epirubicin—Cardiac disorder—Doxorubicin—urinary bladder cancer	4.48e-06	0.000126	CcSEcCtD
Epirubicin—Flushing—Doxorubicin—urinary bladder cancer	4.48e-06	0.000126	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—IGF1—urinary bladder cancer	4.46e-06	0.000331	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PTGS2—urinary bladder cancer	4.43e-06	0.000329	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ENO2—urinary bladder cancer	4.39e-06	0.000326	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—HPGDS—urinary bladder cancer	4.39e-06	0.000326	CbGpPWpGaD
Epirubicin—Angiopathy—Doxorubicin—urinary bladder cancer	4.38e-06	0.000123	CcSEcCtD
Epirubicin—Malaise—Methotrexate—urinary bladder cancer	4.37e-06	0.000123	CcSEcCtD
Epirubicin—Dizziness—Etoposide—urinary bladder cancer	4.37e-06	0.000123	CcSEcCtD
Epirubicin—Immune system disorder—Doxorubicin—urinary bladder cancer	4.36e-06	0.000122	CcSEcCtD
Epirubicin—Vertigo—Methotrexate—urinary bladder cancer	4.36e-06	0.000122	CcSEcCtD
Epirubicin—Mediastinal disorder—Doxorubicin—urinary bladder cancer	4.35e-06	0.000122	CcSEcCtD
Epirubicin—Leukopenia—Methotrexate—urinary bladder cancer	4.34e-06	0.000122	CcSEcCtD
Epirubicin—Chills—Doxorubicin—urinary bladder cancer	4.33e-06	0.000122	CcSEcCtD
Epirubicin—TOP2A—Azacitidine—Gemcitabine—urinary bladder cancer	4.32e-06	0.00545	CbGdCrCtD
Epirubicin—Arrhythmia—Doxorubicin—urinary bladder cancer	4.31e-06	0.000121	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CDKN2A—urinary bladder cancer	4.31e-06	0.00032	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ENO2—urinary bladder cancer	4.3e-06	0.00032	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—HPGDS—urinary bladder cancer	4.3e-06	0.00032	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NAT2—urinary bladder cancer	4.3e-06	0.00032	CbGpPWpGaD
Epirubicin—Nausea—Cisplatin—urinary bladder cancer	4.28e-06	0.00012	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.28e-06	0.000318	CbGpPWpGaD
Epirubicin—Alopecia—Doxorubicin—urinary bladder cancer	4.26e-06	0.00012	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—GSTT1—urinary bladder cancer	4.26e-06	0.000316	CbGpPWpGaD
Epirubicin—Cough—Methotrexate—urinary bladder cancer	4.23e-06	0.000119	CcSEcCtD
Epirubicin—Mental disorder—Doxorubicin—urinary bladder cancer	4.23e-06	0.000119	CcSEcCtD
Epirubicin—Convulsion—Methotrexate—urinary bladder cancer	4.2e-06	0.000118	CcSEcCtD
Epirubicin—Vomiting—Etoposide—urinary bladder cancer	4.2e-06	0.000118	CcSEcCtD
Epirubicin—Malnutrition—Doxorubicin—urinary bladder cancer	4.2e-06	0.000118	CcSEcCtD
Epirubicin—Erythema—Doxorubicin—urinary bladder cancer	4.2e-06	0.000118	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—GSTT1—urinary bladder cancer	4.17e-06	0.00031	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—MYC—urinary bladder cancer	4.17e-06	0.00031	CbGpPWpGaD
Epirubicin—Rash—Etoposide—urinary bladder cancer	4.17e-06	0.000117	CcSEcCtD
Epirubicin—Dermatitis—Etoposide—urinary bladder cancer	4.16e-06	0.000117	CcSEcCtD
Epirubicin—Headache—Etoposide—urinary bladder cancer	4.14e-06	0.000116	CcSEcCtD
Epirubicin—Flatulence—Doxorubicin—urinary bladder cancer	4.14e-06	0.000116	CcSEcCtD
Epirubicin—Arthralgia—Methotrexate—urinary bladder cancer	4.13e-06	0.000116	CcSEcCtD
Epirubicin—Chest pain—Methotrexate—urinary bladder cancer	4.13e-06	0.000116	CcSEcCtD
Epirubicin—Myalgia—Methotrexate—urinary bladder cancer	4.13e-06	0.000116	CcSEcCtD
Epirubicin—Tension—Doxorubicin—urinary bladder cancer	4.12e-06	0.000116	CcSEcCtD
Epirubicin—Dysgeusia—Doxorubicin—urinary bladder cancer	4.11e-06	0.000115	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.11e-06	0.000306	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ENO2—urinary bladder cancer	4.11e-06	0.000305	CbGpPWpGaD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	4.1e-06	0.000115	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—RHOA—urinary bladder cancer	4.08e-06	0.000304	CbGpPWpGaD
Epirubicin—Discomfort—Methotrexate—urinary bladder cancer	4.08e-06	0.000115	CcSEcCtD
Epirubicin—Nervousness—Doxorubicin—urinary bladder cancer	4.08e-06	0.000115	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	4.07e-06	0.000303	CbGpPWpGaD
Epirubicin—Back pain—Doxorubicin—urinary bladder cancer	4.06e-06	0.000114	CcSEcCtD
Epirubicin—Muscle spasms—Doxorubicin—urinary bladder cancer	4.04e-06	0.000113	CcSEcCtD
Epirubicin—Confusional state—Methotrexate—urinary bladder cancer	3.99e-06	0.000112	CcSEcCtD
Epirubicin—Anaphylactic shock—Methotrexate—urinary bladder cancer	3.96e-06	0.000111	CcSEcCtD
Epirubicin—Vision blurred—Doxorubicin—urinary bladder cancer	3.96e-06	0.000111	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	3.94e-06	0.000293	CbGpPWpGaD
Epirubicin—Infection—Methotrexate—urinary bladder cancer	3.93e-06	0.00011	CcSEcCtD
Epirubicin—Nausea—Etoposide—urinary bladder cancer	3.92e-06	0.00011	CcSEcCtD
Epirubicin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	3.9e-06	0.000109	CcSEcCtD
Epirubicin—ABCC1—Disease—RBX1—urinary bladder cancer	3.89e-06	0.000289	CbGpPWpGaD
Epirubicin—Nervous system disorder—Methotrexate—urinary bladder cancer	3.88e-06	0.000109	CcSEcCtD
Epirubicin—Anaemia—Doxorubicin—urinary bladder cancer	3.88e-06	0.000109	CcSEcCtD
Epirubicin—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.87e-06	0.000109	CcSEcCtD
Epirubicin—DHCR7—Metabolism—PTEN—urinary bladder cancer	3.86e-06	0.000287	CbGpPWpGaD
Epirubicin—Agitation—Doxorubicin—urinary bladder cancer	3.86e-06	0.000108	CcSEcCtD
Epirubicin—Skin disorder—Methotrexate—urinary bladder cancer	3.84e-06	0.000108	CcSEcCtD
Epirubicin—Hyperhidrosis—Methotrexate—urinary bladder cancer	3.83e-06	0.000107	CcSEcCtD
Epirubicin—Malaise—Doxorubicin—urinary bladder cancer	3.79e-06	0.000106	CcSEcCtD
Epirubicin—Vertigo—Doxorubicin—urinary bladder cancer	3.77e-06	0.000106	CcSEcCtD
Epirubicin—Anorexia—Methotrexate—urinary bladder cancer	3.77e-06	0.000106	CcSEcCtD
Epirubicin—Syncope—Doxorubicin—urinary bladder cancer	3.77e-06	0.000106	CcSEcCtD
Epirubicin—Leukopenia—Doxorubicin—urinary bladder cancer	3.76e-06	0.000106	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—EP300—urinary bladder cancer	3.75e-06	0.000279	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—RRM2—urinary bladder cancer	3.71e-06	0.000276	CbGpPWpGaD
Epirubicin—Palpitations—Doxorubicin—urinary bladder cancer	3.71e-06	0.000104	CcSEcCtD
Epirubicin—Hypotension—Methotrexate—urinary bladder cancer	3.7e-06	0.000104	CcSEcCtD
Epirubicin—Loss of consciousness—Doxorubicin—urinary bladder cancer	3.69e-06	0.000104	CcSEcCtD
Epirubicin—DHCR7—Metabolism—EP300—urinary bladder cancer	3.68e-06	0.000274	CbGpPWpGaD
Epirubicin—Cough—Doxorubicin—urinary bladder cancer	3.66e-06	0.000103	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CCND1—urinary bladder cancer	3.64e-06	0.000271	CbGpPWpGaD
Epirubicin—Convulsion—Doxorubicin—urinary bladder cancer	3.64e-06	0.000102	CcSEcCtD
Epirubicin—Hypertension—Doxorubicin—urinary bladder cancer	3.63e-06	0.000102	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.61e-06	0.000101	CcSEcCtD
Epirubicin—Insomnia—Methotrexate—urinary bladder cancer	3.58e-06	0.000101	CcSEcCtD
Epirubicin—Arthralgia—Doxorubicin—urinary bladder cancer	3.57e-06	0.0001	CcSEcCtD
Epirubicin—Chest pain—Doxorubicin—urinary bladder cancer	3.57e-06	0.0001	CcSEcCtD
Epirubicin—Myalgia—Doxorubicin—urinary bladder cancer	3.57e-06	0.0001	CcSEcCtD
Epirubicin—Anxiety—Doxorubicin—urinary bladder cancer	3.56e-06	0.0001	CcSEcCtD
Epirubicin—Paraesthesia—Methotrexate—urinary bladder cancer	3.55e-06	9.98e-05	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	3.55e-06	9.97e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—NQO1—urinary bladder cancer	3.54e-06	0.000263	CbGpPWpGaD
Epirubicin—Discomfort—Doxorubicin—urinary bladder cancer	3.53e-06	9.92e-05	CcSEcCtD
Epirubicin—Dyspnoea—Methotrexate—urinary bladder cancer	3.53e-06	9.91e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CDKN1A—urinary bladder cancer	3.52e-06	0.000262	CbGpPWpGaD
Epirubicin—Somnolence—Methotrexate—urinary bladder cancer	3.52e-06	9.88e-05	CcSEcCtD
Epirubicin—Dry mouth—Doxorubicin—urinary bladder cancer	3.5e-06	9.82e-05	CcSEcCtD
Epirubicin—Dyspepsia—Methotrexate—urinary bladder cancer	3.48e-06	9.78e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—JAG1—urinary bladder cancer	3.48e-06	0.000259	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—NQO1—urinary bladder cancer	3.47e-06	0.000258	CbGpPWpGaD
Epirubicin—Confusional state—Doxorubicin—urinary bladder cancer	3.46e-06	9.7e-05	CcSEcCtD
Epirubicin—Decreased appetite—Methotrexate—urinary bladder cancer	3.44e-06	9.66e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—HPGDS—urinary bladder cancer	3.44e-06	0.000256	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ENO2—urinary bladder cancer	3.44e-06	0.000256	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—urinary bladder cancer	3.43e-06	0.000255	CbGpPWpGaD
Epirubicin—Oedema—Doxorubicin—urinary bladder cancer	3.43e-06	9.62e-05	CcSEcCtD
Epirubicin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	3.43e-06	9.62e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—IL2—urinary bladder cancer	3.43e-06	0.000255	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.42e-06	0.000254	CbGpPWpGaD
Epirubicin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.42e-06	9.59e-05	CcSEcCtD
Epirubicin—Fatigue—Methotrexate—urinary bladder cancer	3.41e-06	9.58e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—RBX1—urinary bladder cancer	3.41e-06	0.000254	CbGpPWpGaD
Epirubicin—Infection—Doxorubicin—urinary bladder cancer	3.4e-06	9.56e-05	CcSEcCtD
Epirubicin—Pain—Methotrexate—urinary bladder cancer	3.38e-06	9.5e-05	CcSEcCtD
Epirubicin—Shock—Doxorubicin—urinary bladder cancer	3.37e-06	9.47e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.37e-06	0.00025	CbGpPWpGaD
Epirubicin—Nervous system disorder—Doxorubicin—urinary bladder cancer	3.36e-06	9.44e-05	CcSEcCtD
Epirubicin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.36e-06	9.42e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—EP300—urinary bladder cancer	3.35e-06	0.000249	CbGpPWpGaD
Epirubicin—Tachycardia—Doxorubicin—urinary bladder cancer	3.34e-06	9.39e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—GSTT1—urinary bladder cancer	3.33e-06	0.000248	CbGpPWpGaD
Epirubicin—Skin disorder—Doxorubicin—urinary bladder cancer	3.33e-06	9.35e-05	CcSEcCtD
Epirubicin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	3.31e-06	9.3e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.28e-06	0.000244	CbGpPWpGaD
Epirubicin—Anorexia—Doxorubicin—urinary bladder cancer	3.27e-06	9.17e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—MYC—urinary bladder cancer	3.26e-06	0.000243	CbGpPWpGaD
Epirubicin—Feeling abnormal—Methotrexate—urinary bladder cancer	3.26e-06	9.16e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.24e-06	9.09e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—TSC1—urinary bladder cancer	3.21e-06	0.000238	CbGpPWpGaD
Epirubicin—Hypotension—Doxorubicin—urinary bladder cancer	3.2e-06	8.99e-05	CcSEcCtD
Epirubicin—Urticaria—Methotrexate—urinary bladder cancer	3.14e-06	8.83e-05	CcSEcCtD
Epirubicin—Body temperature increased—Methotrexate—urinary bladder cancer	3.13e-06	8.79e-05	CcSEcCtD
Epirubicin—Abdominal pain—Methotrexate—urinary bladder cancer	3.13e-06	8.79e-05	CcSEcCtD
Epirubicin—ABCC1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.12e-06	0.000232	CbGpPWpGaD
Epirubicin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.12e-06	8.77e-05	CcSEcCtD
Epirubicin—Insomnia—Doxorubicin—urinary bladder cancer	3.1e-06	8.7e-05	CcSEcCtD
Epirubicin—Paraesthesia—Doxorubicin—urinary bladder cancer	3.08e-06	8.64e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—EP300—urinary bladder cancer	3.07e-06	0.000229	CbGpPWpGaD
Epirubicin—Dyspnoea—Doxorubicin—urinary bladder cancer	3.06e-06	8.58e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—JAG1—urinary bladder cancer	3.05e-06	0.000227	CbGpPWpGaD
Epirubicin—Somnolence—Doxorubicin—urinary bladder cancer	3.05e-06	8.55e-05	CcSEcCtD
Epirubicin—Dyspepsia—Doxorubicin—urinary bladder cancer	3.02e-06	8.47e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—SRC—urinary bladder cancer	2.99e-06	0.000222	CbGpPWpGaD
Epirubicin—Decreased appetite—Doxorubicin—urinary bladder cancer	2.98e-06	8.37e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.96e-06	8.31e-05	CcSEcCtD
Epirubicin—Fatigue—Doxorubicin—urinary bladder cancer	2.95e-06	8.3e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—GSTP1—urinary bladder cancer	2.95e-06	0.000219	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.93e-06	0.000218	CbGpPWpGaD
Epirubicin—Constipation—Doxorubicin—urinary bladder cancer	2.93e-06	8.23e-05	CcSEcCtD
Epirubicin—Pain—Doxorubicin—urinary bladder cancer	2.93e-06	8.23e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—MYC—urinary bladder cancer	2.92e-06	0.000217	CbGpPWpGaD
Epirubicin—Hypersensitivity—Methotrexate—urinary bladder cancer	2.92e-06	8.19e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—GSTP1—urinary bladder cancer	2.89e-06	0.000215	CbGpPWpGaD
Epirubicin—Asthenia—Methotrexate—urinary bladder cancer	2.84e-06	7.97e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.82e-06	7.93e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.8e-06	7.87e-05	CcSEcCtD
Epirubicin—Pruritus—Methotrexate—urinary bladder cancer	2.8e-06	7.86e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.8e-06	0.000208	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NQO1—urinary bladder cancer	2.77e-06	0.000206	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—TYMS—urinary bladder cancer	2.74e-06	0.000204	CbGpPWpGaD
Epirubicin—Urticaria—Doxorubicin—urinary bladder cancer	2.72e-06	7.64e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—NCOR1—urinary bladder cancer	2.71e-06	0.000202	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GSTM1—urinary bladder cancer	2.71e-06	0.000202	CbGpPWpGaD
Epirubicin—Abdominal pain—Doxorubicin—urinary bladder cancer	2.71e-06	7.61e-05	CcSEcCtD
Epirubicin—Body temperature increased—Doxorubicin—urinary bladder cancer	2.71e-06	7.61e-05	CcSEcCtD
Epirubicin—Diarrhoea—Methotrexate—urinary bladder cancer	2.71e-06	7.6e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—TYMS—urinary bladder cancer	2.69e-06	0.0002	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.69e-06	0.0002	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—GSTM1—urinary bladder cancer	2.66e-06	0.000198	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—NCOR1—urinary bladder cancer	2.66e-06	0.000198	CbGpPWpGaD
Epirubicin—Dizziness—Methotrexate—urinary bladder cancer	2.62e-06	7.35e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—GPX1—urinary bladder cancer	2.6e-06	0.000193	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ERCC2—urinary bladder cancer	2.55e-06	0.00019	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—GPX1—urinary bladder cancer	2.55e-06	0.000189	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NCOR1—urinary bladder cancer	2.54e-06	0.000189	CbGpPWpGaD
Epirubicin—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.52e-06	7.09e-05	CcSEcCtD
Epirubicin—Vomiting—Methotrexate—urinary bladder cancer	2.52e-06	7.07e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—ERCC2—urinary bladder cancer	2.5e-06	0.000186	CbGpPWpGaD
Epirubicin—Rash—Methotrexate—urinary bladder cancer	2.5e-06	7.01e-05	CcSEcCtD
Epirubicin—Dermatitis—Methotrexate—urinary bladder cancer	2.49e-06	7e-05	CcSEcCtD
Epirubicin—Headache—Methotrexate—urinary bladder cancer	2.48e-06	6.96e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—KRAS—urinary bladder cancer	2.48e-06	0.000184	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—S100B—urinary bladder cancer	2.47e-06	0.000184	CbGpPWpGaD
Epirubicin—Asthenia—Doxorubicin—urinary bladder cancer	2.46e-06	6.9e-05	CcSEcCtD
Epirubicin—Pruritus—Doxorubicin—urinary bladder cancer	2.42e-06	6.81e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—TP53—urinary bladder cancer	2.4e-06	0.000178	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—MTHFR—urinary bladder cancer	2.4e-06	0.000178	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ERCC2—urinary bladder cancer	2.38e-06	0.000177	CbGpPWpGaD
Epirubicin—Nausea—Methotrexate—urinary bladder cancer	2.35e-06	6.6e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—MTHFR—urinary bladder cancer	2.35e-06	0.000175	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.34e-06	0.000174	CbGpPWpGaD
Epirubicin—Diarrhoea—Doxorubicin—urinary bladder cancer	2.34e-06	6.58e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—RHOA—urinary bladder cancer	2.34e-06	0.000174	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GSTP1—urinary bladder cancer	2.31e-06	0.000172	CbGpPWpGaD
Epirubicin—Dizziness—Doxorubicin—urinary bladder cancer	2.27e-06	6.36e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—MTHFR—urinary bladder cancer	2.24e-06	0.000167	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.24e-06	0.000166	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TERT—urinary bladder cancer	2.24e-06	0.000166	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NCOR1—urinary bladder cancer	2.22e-06	0.000165	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TP53—urinary bladder cancer	2.2e-06	0.000164	CbGpPWpGaD
Epirubicin—Vomiting—Doxorubicin—urinary bladder cancer	2.18e-06	6.12e-05	CcSEcCtD
Epirubicin—Rash—Doxorubicin—urinary bladder cancer	2.16e-06	6.07e-05	CcSEcCtD
Epirubicin—Dermatitis—Doxorubicin—urinary bladder cancer	2.16e-06	6.06e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—TYMS—urinary bladder cancer	2.15e-06	0.00016	CbGpPWpGaD
Epirubicin—Headache—Doxorubicin—urinary bladder cancer	2.15e-06	6.03e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—GSTM1—urinary bladder cancer	2.12e-06	0.000158	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NCOR1—urinary bladder cancer	2.12e-06	0.000158	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—HRAS—urinary bladder cancer	2.1e-06	0.000156	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CXCL8—urinary bladder cancer	2.06e-06	0.000153	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FGFR3—urinary bladder cancer	2.05e-06	0.000153	CbGpPWpGaD
Epirubicin—Nausea—Doxorubicin—urinary bladder cancer	2.04e-06	5.72e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—GPX1—urinary bladder cancer	2.03e-06	0.000151	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ERCC2—urinary bladder cancer	2e-06	0.000148	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL2—urinary bladder cancer	1.97e-06	0.000146	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TERT—urinary bladder cancer	1.96e-06	0.000146	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PPARG—urinary bladder cancer	1.94e-06	0.000144	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PPARG—urinary bladder cancer	1.91e-06	0.000142	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—MTHFR—urinary bladder cancer	1.88e-06	0.00014	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CREBBP—urinary bladder cancer	1.87e-06	0.000139	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CREBBP—urinary bladder cancer	1.83e-06	0.000136	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FGFR3—urinary bladder cancer	1.8e-06	0.000134	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ESR1—urinary bladder cancer	1.75e-06	0.00013	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CREBBP—urinary bladder cancer	1.75e-06	0.00013	CbGpPWpGaD
Epirubicin—ABCC1—Disease—RHOA—urinary bladder cancer	1.58e-06	0.000117	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CREBBP—urinary bladder cancer	1.53e-06	0.000114	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTGS2—urinary bladder cancer	1.53e-06	0.000114	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PPARG—urinary bladder cancer	1.52e-06	0.000113	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IGF1—urinary bladder cancer	1.51e-06	0.000112	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—EGFR—urinary bladder cancer	1.5e-06	0.000112	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTGS2—urinary bladder cancer	1.5e-06	0.000111	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CREBBP—urinary bladder cancer	1.46e-06	0.000109	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ERBB2—urinary bladder cancer	1.46e-06	0.000109	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTGS2—urinary bladder cancer	1.43e-06	0.000106	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—KRAS—urinary bladder cancer	1.42e-06	0.000106	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—RHOA—urinary bladder cancer	1.38e-06	0.000103	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTEN—urinary bladder cancer	1.33e-06	9.91e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTEN—urinary bladder cancer	1.31e-06	9.72e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ERBB2—urinary bladder cancer	1.28e-06	9.53e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—EP300—urinary bladder cancer	1.27e-06	9.45e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CDKN1A—urinary bladder cancer	1.25e-06	9.29e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTEN—urinary bladder cancer	1.25e-06	9.27e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—EP300—urinary bladder cancer	1.25e-06	9.27e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCL8—urinary bladder cancer	1.22e-06	9.04e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—HRAS—urinary bladder cancer	1.21e-06	8.98e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTGS2—urinary bladder cancer	1.2e-06	8.9e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EP300—urinary bladder cancer	1.19e-06	8.84e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL2—urinary bladder cancer	1.16e-06	8.64e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SRC—urinary bladder cancer	1.16e-06	8.6e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCND1—urinary bladder cancer	1.13e-06	8.42e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MMP9—urinary bladder cancer	1.1e-06	8.17e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.1e-06	8.14e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTEN—urinary bladder cancer	1.09e-06	8.13e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTEN—urinary bladder cancer	1.04e-06	7.76e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EP300—urinary bladder cancer	1.04e-06	7.75e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MYC—urinary bladder cancer	1.04e-06	7.71e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EGFR—urinary bladder cancer	1.01e-06	7.54e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SRC—urinary bladder cancer	1.01e-06	7.54e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—EP300—urinary bladder cancer	9.96e-07	7.41e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KRAS—urinary bladder cancer	9.57e-07	7.12e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MYC—urinary bladder cancer	9.08e-07	6.75e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EGFR—urinary bladder cancer	8.88e-07	6.61e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KRAS—urinary bladder cancer	8.39e-07	6.24e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HRAS—urinary bladder cancer	8.14e-07	6.05e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—urinary bladder cancer	7.46e-07	5.55e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HRAS—urinary bladder cancer	7.13e-07	5.3e-05	CbGpPWpGaD
